Shu‐Fen Chiang

2.3k citations
55 papers · 1.6k indexed · h-index 26
Topics
Cancer Immunotherapy and Biomarkers (25 papers)Immunotherapy and Immune Responses (10 papers)Colorectal Cancer Treatments and Studies (9 papers)
Partner nations
TaiwanJapanUnited States

In The Last Decade

Shu‐Fen Chiang

52 papers receiving 1.6k citations

Peers

Shu‐Fen Chiang
Comparison fields: 5 of 89
  • Molecular Biology 725
  • Oncology 694
  • Immunology 504
  • Cancer Research 238
  • Epidemiology 219
Replace Xiao-Shi Zhang with:
Xiao-Shi Zhang China
Kousaku Mimura Japan
Dongli Yue China
Miguel Reina‐Campos United States
Fabien Franco Switzerland
Guo‐Ming Shi China
Dan Dumont Canada
Dorota Wyczechowska United States
Jong Woo Lee South Korea
Shu‐Fen Chiang relative to Xiao-Shi Zhang China Xiao-Shi Zhang's profile →
Citations per field
00.5×2.5×
Xiao-Shi Zhang · 1×
Citations per year

Countries citing papers authored by Shu‐Fen Chiang

Since Specialization
Citations

This map shows the geographic impact of Shu‐Fen Chiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu‐Fen Chiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu‐Fen Chiang more than expected).

Fields of papers citing papers by Shu‐Fen Chiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu‐Fen Chiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu‐Fen Chiang. The network helps show where Shu‐Fen Chiang may publish in the future.

Co-authorship network of co-authors of Shu‐Fen Chiang

This figure shows the co-authorship network connecting the top 25 collaborators of Shu‐Fen Chiang. A scholar is included among the top collaborators of Shu‐Fen Chiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu‐Fen Chiang. Shu‐Fen Chiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 10
3 25
4 3
5 0
6 4
7 26
8 38
9 31
10 38
11 16
12 10
13 282
14 45
15 27
16 52
17 62
18 46
19 40
20 16

About Shu‐Fen Chiang

Shu‐Fen Chiang is a scholar working on Oncology, Immunology and Physiology, having authored 55 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (25 papers), Immunotherapy and Immune Responses (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). The work is most often cited by research in Oncology (694 citations), Immunology (504 citations) and Cancer Research (238 citations). Shu‐Fen Chiang has collaborated with scholars based in Taiwan, Japan and United States. Frequent co-authors include K. S. Clifford Chao, Kevin Chih‐Yang Huang, Tao‐Wei Ke, William Tzu‐Liang Chen, Tsung-Wei Chen, Kuan‐Chih Chow, Shyh‐Horng Chiou, Ying‐Shu You, Chih‐Yang Huang and Tze‐Yi Lin. Their work appears in journals such as Nature Communications, Cancer Cell and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026